Livionex - also doing business as LIVFRESH Dental (launched in 2013) - is a platform technology company focused on oral care, ophthalmology and wound care. Livionex had been described as an early stage pharmaceutical company whose first two products treat early cataract and inflammatory disorders. At one point, Livionex was in stealth mode addressing developiment of eye drops designed to help prevent cataracts. In the Spring 2019, Livionex emerged from stealth mode to raise $4mm in an over-subscribed Series A financing involving private investors and family officers. At that point the firm also shifted emphasis to a focus on development and sale of a product - distributed through Livionex - tp the prevention & treatment of plaque build-up.
